FDA warns Skye Biologics its umbilical cord-derived BioECM products are unapproved drugs and unlicensed biologics, made with serious manufacturing (CGMP) failures.
What happened
FDA inspected Skye Biologics' El Segundo, California facility from November 29 to December 9, 2022, and also reviewed the company's website, press releases and records. FDA found the company markets umbilical cord-derived BioECM products with claims such as anti-inflammatory, anti-fibrotic and tissue-remodeling effects, which make them drugs and biological products sold without an approved license, and that its processing changes the tissue more than minimally and is not for homologous use. The inspection also turned up CGMP (current good manufacturing practice, the rules for how drugs must be made) failures in process validation, aseptic processing controls, testing and batch records.
What FDA found
The products are unapproved new drugs and unlicensed biological products because no biologics license (BLA) is in effect for them.
Section 505(a) FD&C Act, 21 U.S.C. 355(a); section 351(a) PHS Act, 42 U.S.C. 262(a)The company never validated its manufacturing processes to show the products have the identity, strength, quality and purity they claim.
21 CFR 211.100(a)Environmental and personnel monitoring in the ISO 5 laminar flow hoods was inadequate, and the hoods sat in an unclassified room.
21 CFR 211.42(c)(10)(iv); 21 CFR 211.113(b)The company did not test final product batches for endotoxin (bacterial toxin) even though the products are claimed to be sterile.
21 CFR 211.165(b)Three environmental monitoring results above the action level between January 2021 and August 2022 were never investigated.
21 CFR 211.192Batch records left out key manufacturing steps, and a five-year expiration date was set without stability data to support it.
21 CFR 211.188(b); 21 CFR 211.166(a)
What FDA wants
FDA tells the company to respond in writing within 15 working days with the specific corrective steps taken or planned, supporting documentation, and an explanation of how it will prevent repeat violations. It also asks the company to explain why BioRenew, HRT BioPower-A, HRT BioPower-C and HRT NX do or do not need FDA premarket review.
Who should pay attention
- clinics and surgeons implanting placental or umbilical cord allografts
- distributors and brands selling BioECM or HRT products
- tissue banks and HCT/P makers relying on the section 361 pathway
This is a summary. Read the original letter on fda.gov.